tiprankstipranks
Advertisement
Advertisement

IOVA Stock Latest News

Iovance updates outlook, highlighting Amtagvi growth and pipeline
Company AnnouncementsIovance updates outlook, highlighting Amtagvi growth and pipeline
19d ago
8K
IOVA
Iovance Biotherapeutics files automatic mixed securities shelf
PremiumThe Fly
Iovance Biotherapeutics files automatic mixed securities shelf
1M ago
IOVA
Iovance Shareholders Approve Expanded Capital Flexibility and Governance
PremiumCompany Announcements
Iovance Shareholders Approve Expanded Capital Flexibility and Governance
1M ago
8K
IOVA
Joseph Pantginis Maintains Buy Rating on Iovance as AMTAGVI’s Global Expansion and Survival Data Support Unchanged $9 Price Target
PremiumRatings
Joseph Pantginis Maintains Buy Rating on Iovance as AMTAGVI’s Global Expansion and Survival Data Support Unchanged $9 Price Target
2M ago
IOVA
Iovance receives Australian approval of Amtagvi for advanced melanoma
PremiumThe Fly
Iovance receives Australian approval of Amtagvi for advanced melanoma
2M ago
IOVA
Iovance gets allowance to proceed from FDA for IOV-5001 IND application
PremiumThe FlyIovance gets allowance to proceed from FDA for IOV-5001 IND application
2M ago
IOVA
Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth
Premium
Company Announcements
Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth
2M ago
IOVA
Iovance Biotherapeutics Signals Strong Momentum in Call
Premium
Company Announcements
Iovance Biotherapeutics Signals Strong Momentum in Call
2M ago
IOVA
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan
PremiumThe Fly
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan
2M ago
IOVA
Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
PremiumThe Fly
Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
3M ago
IOVA
Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
PremiumThe Fly
Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
3M ago
IOVA
Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
PremiumThe Fly
Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
3M ago
IOVA
Unusually active option classes on open May 6th
PremiumThe FlyUnusually active option classes on open May 6th
3M ago
AG
DIS
Iovance Biotherapeutics (IOVA) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Iovance Biotherapeutics (IOVA) Q1 Earnings Cheat Sheet
3M ago
IOVA
Replimune CRL positive for Iovance in near-term, says Chardan
Premium
The Fly
Replimune CRL positive for Iovance in near-term, says Chardan
3M ago
IOVA
REPL
Iovance could advance 5%-15% on Replimune rejection, says Jefferies
PremiumThe Fly
Iovance could advance 5%-15% on Replimune rejection, says Jefferies
3M ago
IOVA
REPL
Unusually active option classes on open April 10th
PremiumThe Fly
Unusually active option classes on open April 10th
3M ago
AMC
AMD
Iovance Biotherapeutics Announces Upcoming Board Member Retirement
PremiumCompany Announcements
Iovance Biotherapeutics Announces Upcoming Board Member Retirement
4M ago
8K
IOVA
Iovance Biotherapeutics call volume above normal and directionally bullish
PremiumThe Fly
Iovance Biotherapeutics call volume above normal and directionally bullish
5M ago
IOVA
Iovance Biotherapeutics price target raised to $4 from $2 at UBS
PremiumThe FlyIovance Biotherapeutics price target raised to $4 from $2 at UBS
5M ago
IOVA
Iovance Biotherapeutics Signals Strong Momentum In Earnings
Premium
Company Announcements
Iovance Biotherapeutics Signals Strong Momentum In Earnings
5M ago
IOVA
Iovance Biotherapeutics price target raised to $4 from $3 at Baird
Premium
The Fly
Iovance Biotherapeutics price target raised to $4 from $3 at Baird
5M ago
IOVA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >